Eli Lilly and Company to Acquire Mablink Bioscience

Mablink Bioscience, a pre-clinical biotechnology company developing antibody-drug conjugates (ADCs) with its PSARLink technology, has entered an agreement to be acquired by Eli Lilly and Company. The acquisition is positioned to expand Mablink’s ADC pipeline and leverage PSARLink to develop additional drug conjugates, subject to French Ministry of the Economy approval.